



Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006.

**U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                          |                     |
|---|---|--------------------------|---------------------|
| Substitute for form 1449/PTO  |   | <i>Complete if Known</i> |                     |
| <b>NINTH SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   | Application Number       | 09/921,143          |
|   |   | Filing Date              | August 3, 2001      |
|   |   | First Named Inventor     | Coleman, Timothy A. |
|   |   | Art Unit                 | 1636                |
|   |   | Examiner Name            | Qian, Celine X.     |
| Sheet   | 1 | of                       | 2                   |
|   |   | Attorney Docket Number   |                     |
|   |   | 1488.10000N/HCC/PAC      |                     |

## **FOREIGN PATENT DOCUMENTS**


| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document     | Pages, Columns,<br>Lines, Where<br>Relevant Passages or<br>Relevant Figures<br>Appear | T <sup>6</sup> |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
|                    |                       | Country Code <sup>1</sup> Number <sup>1</sup> Kind Code <sup>1</sup> (if known) |                                |  |   |                |
| CQ                 | FP1                   | EP 0 186 084 A2   | 07/02/1986                     | Merck & Co. Inc.                                       |   |                |
|                    | FP2                   | JP 64-38100 A   | 02/08/1989                     | Toray Ind. Inc.  |   |                |
|                    | FP3                   | JP 2-117698 A   | 05/02/1990                     | Ajinomoto KK and Toray<br>Ind. Inc.                    |   |                |
|                    | FP4                   | EP 0 399 816 A1   | 11/28/1990                     | Merck & Co. Inc.                                       |   |                |
|                    | FP5                   | WO 94/11506 A1  | 05/26/1994                     | Arch Development<br>Corporation                        |   |                |
|                    | FP6                   | WO 97/17442 A1  | 05/15/1997                     | Immunex Corporation                                    |   |                |
|                    | FP7                   | WO 00/45835 A1  | 08/10/2000                     | Human Genome Sciences,<br>Inc. and Rosen <i>et al.</i> |   |                |
|                    | FP8                   | WO 02/11769 A1  | 02/14/2002                     | Human Genome Sciences,<br>Inc. and Coleman             |   |                |
| ↓                  | FP9                   | WO 02/083704 A1   | 10/24/2002                     | Human Genome Sciences,<br>Inc. and Rosen <i>et al.</i> |   |                |

|                       |               |                    |  |
|-----------------------|---------------|--------------------|--|
| Examiner<br>Signature | /Celine Qian/ | Date<br>Considered |  |
|-----------------------|---------------|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006.

Approved for use through 07/01/2006.  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

|   |   |    |   |                          |                      |
|---|---|----|---|--------------------------|----------------------|
| Substitute for form 1449/PTO  |   |    |   | <i>Complete if Known</i> |                      |
| <b>NINTH SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | Application Number       | 09/921,143           |
|   |   |    |   | Filing Date              | August 3, 2001       |
|   |   |    |   | First Named Inventor     | Coleman, Timothy A.  |
|   |   |    |   | Art Unit                 | 1636                 |
|   |   |    |   | Examiner Name            | Qian, Celine X.      |
| Sheet   | 2 | of | 2 | Attorney Docket Number   | 1488.100000N/HCC/PAC |

## U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document     | Pages, Columns,<br>Lines, Where<br>Relevant Passages or<br>Relevant Figures<br>Appear | T <sup>6</sup> |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
|                    |                       | Country Code <sup>2</sup> Number <sup>3</sup> Kind Code <sup>4</sup> (if known) |                                |  |   |                |
| CQ                 | FP10                  | WO 02/083849 A2   | 10/24/2002                     | Human Genome Sciences,<br>Inc. and Rosen <i>et al.</i> |   |                |
| ↓                  | FP11                  | WO 02/083850 A2   | 10/24/2002                     | Human Genome Sciences,<br>Inc. and Rosen <i>et al.</i> |   |                |
| ↓                  | FP12                  | WO 03/097660 A1   | 11/27/2003                     | Human Genome Sciences,<br>Inc. and Rosen <i>et al.</i> |   |                |
|                    |                       |   |                                |  |   |                |
|                    |                       |   |                                |  |   |                |
|                    |                       |   |                                |  |   |                |
|                    |                       |   |                                |  |   |                |

504081\_1.DOC

|                       |               |                    |  |
|-----------------------|---------------|--------------------|--|
| Examiner<br>Signature | /Celine Qian/ | Date<br>Considered |  |
|-----------------------|---------------|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|                              |   |    |   |                          |                      |
|------------------------------|---|----|---|--------------------------|----------------------|
| Substitute for form 1449/PTO |   |    |   | <i>Complete if Known</i> |                      |
|                              |   |    |   | Application Number       | 09/921,143           |
|                              |   |    |   | Filing Date              | August 3, 2001       |
|                              |   |    |   | First Named Inventor     | Coleman, Timothy A.  |
|                              |   |    |   | Art Unit                 | 1636                 |
|                              |   |    |   | Examiner Name            | Qian, Celine X.      |
| Sheet                        | 1 | of | 5 | Attorney Docket Number   | 1488.100000N/HCC/PAC |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published              | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
| CQ                 | NPL1                  | Danis, R.P., <i>et al.</i> , "Anti-angiogenic therapy of proliferative diabetic retinopathy," <i>Exp. Opin. Pharma.</i> 2:395-407, Ashley Publications Ltd. (March 2001)  |                |
|                    | NPL2                  | Enholm, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood," <i>Trends Cardiovascular Med.</i> 8:292-297, Elsevier Science, Inc. (October 1998)   |                |
|                    | NPL3                  | Ferrara, N., "Vascular Endothelial Growth Factor and the Regulation of angiogenesis," <i>Recent Prog. Hormone Res.</i> 55:15-36, The Endocrine Society (March 2000)   |                |
|                    | NPL4                  | Halin, C. and Neri, D., "Antibody-Based Targeting of Angiogenesis," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> 18:299-339, Begell House, Inc. (August 2001)   |                |
|                    | NPL5                  | Longo, R., <i>et al.</i> , "Anti-angiogenic therapy: Rationale, challenges and clinical studies," <i>Angiogenesis</i> 5:237-256, Kluwer Academic Publishers (December 2002)   |                |
|                    | NPL6                  | Schlaeppi, J.-M., <i>et al.</i> , "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor," <i>J. Cancer Res. Clin. Oncol.</i> 125:336-342, Springer-Verlag (May 1999)                                      |                |
|                    | NPL7                  | van der Flier, M., <i>et al.</i> , "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis," <i>J. Neuroimmunol.</i> 160:170-177, Elsevier B.V. (March 2005) |                |
|                    | NPL8                  | Walsh, D.A., "Angiogenesis and arthritis," <i>Rheumatology</i> 38:103-112, British Society for Rheumatology (February 1999)   |                |
|                    | NPL9                  | Winkler, K., <i>et al.</i> , "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody," <i>J. Immunol.</i> 165:4505-4514, The American Association of Immunologists (October 2000)   |                |
| ✓                  | NPL10                 | NCBI Entrez, GenBank Report, Accession No. AF010302, Mandriota S.J. and Pepper, M.S., Entry date July 1997  |                |

|                    |               |                 |
|--------------------|---------------|-----------------|
| Examiner Signature | /Celine Qian/ | Date Considered |
|--------------------|---------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                          |                      |
|---|---|--------------------------|----------------------|
| Substitute for form 1449/PTO<br><br><b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   | <b>Complete if Known</b> |                      |
|   |   | Application Number       | 09/921,143           |
|   |   | Filing Date              | August 3, 2001       |
|   |   | First Named Inventor     | Coleman, Timothy A.  |
|   |   | Art Unit                 | 1636                 |
|   |   | Examiner Name            | Qian, Celine X.      |
| Sheet   | 2 | of                       | 5                    |
|   |   | Attorney Docket Number   | 1488.100000N/HCC/PAC |

| <b>NON PATENT LITERATURE DOCUMENTS</b> |                       |  |  |                |
|--|-----------------------|--|--|----------------|
| Examiner Initials*                     | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published |  | T <sup>2</sup> |
| CQ                                     | NPL11                 | Anderson, W.F., "Human gene therapy," <i>Nature</i> 392:25-30, Macmillan Magazines Ltd. (April 1998)   |  |                |
|  | NPL12                 | Borg, J.-P., et al., "Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase," <i>Oncogene</i> 10:973-984, Stockton Press (March 1995)  |  |                |
|  | NPL13                 | Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01AG00811-01, Abstract (January 1994)  |  |                |
|  | NPL14                 | Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01AG00811-02, Abstract (January 1995)  |  |                |
|  | NPL15                 | Choi, I.H., et al., "Angiogenesis and Mineralization During Distraction Osteogenesis," <i>J. Korean Med. Sci.</i> 17:435-447, The Korean Academy of Medical Sciences (August 2002)   |  |                |
|  | NPL16                 | Copy of Declaration of Dr. Karl Alitalo, In re of : U.S. Application No. 08/585,895, Alitalo et al., filed January 12, 1996, submitted November 26, 1997   |  |                |
|  | NPL17                 | Dias, S., et al., "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," <i>Blood</i> 99:2179-2184, The American Society of Hematology (March 2002)   |  |                |
|  | NPL18                 | English language abstract of JP 64-38100A, cited as document FP2 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912  |  |                |
|  | NPL19                 | English language abstract of JP 2-117698 A, cited as document FP3 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024   |  |                |
|  | NPL20                 | Fan, T.-P., et al., "Controlling the vasculare: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Trends Pharmacol. Sci.</i> 16:57-66, Elsevier Science Ltd. (February 1995)   |  |                |
| ▼                                      | NPL21                 | Isner, J.M., et al., "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," <i>Circulation</i> 91:2687-2692, American Heart Association, Inc. (June 1995)  |  |                |

|                    |               |                 |
|--------------------|---------------|-----------------|
| Examiner Signature | /Celine Qian/ | Date Considered |
|--------------------|---------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                     |
|---|---|----|---|--------------------------|---------------------|
| Substitute for form 1449/PTO  |   |    |   | <i>Complete if Known</i> |                     |
| <b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | Application Number       | 09/921,143          |
| Sheet   | 3 | of | 5 | Filing Date              | August 3, 2001      |
|   |   |    |   | First Named Inventor     | Coleman, Timothy A. |
|   |   |    |   | Art Unit                 | 1636                |
|   |   |    |   | Examiner Name            | Qian, Celine X.     |
|   |   |    |   | Attorney Docket Number   | 1488.10000N/HCC/PAC |

| NON PATENT LITERATURE DOCUMENTS |                       |  |  |  |                |
|---------------------------------|-----------------------|--|--|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published            |  |  |                |
| CQ                              | NPL22                 | Isner, J.M., et al., "Gene therapy for arterial disease," <i>Lancet</i> 344:1653-1654, The Lancet Ltd. (December 1994)   |  |  | T <sup>2</sup> |
|                                 | NPL23                 | Isner, J.M., et al., "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth," <i>J. Cell. Biochem. (Suppl. 21A)</i> :378, Abstract C6-215, Wiley-Liss (March-April 1995)  |  |  |                |
|                                 | NPL24                 | Isner, J.M., et al., "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL5335401, Abstract (March 1995)   |  |  |                |
|                                 | NPL25                 | Kubo, H., et al., "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblasts growth factor-2-induced lymphangiogenesis in mouse cornea," <i>Proc. Natl. Acad. Sci.</i> 99:8868-8873, The National Academy of Sciences (June 2002) |  |  |                |
|                                 | NPL26                 | Kuzuya, M. and Kinsella, J.L., "Induction of Endothelial Cell differentiation In Vitro by Fibroblast-Derived Soluble Factors," <i>Exp. Cell Res.</i> 215:310-318, Academic Press, Inc.(December 1994)  |  |  |                |
|                                 | NPL27                 | Maher, P.A., "Stimulation of Endothelial Cell Proliferation by Vanadate Is Specific for Microvascular Endothelial Cells," <i>J. Cell. Physiol.</i> 151:549-554, Wiley-Liss, Inc. (1992)  |  |  |                |
|                                 | NPL28                 | Maynard, J. and Georgiou, G., "Antibody Engineering," <i>Annu. Rev. Biomed. Eng.</i> 2:339-376, Annual Reviews (August 2000)   |  |  |                |
|                                 | NPL29                 | Mesri, E.A., et al., "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type I Amplicon Vector Induces Angiogenesis in Mice," <i>Circulation Res.</i> 76:161-167, American Heart Association, Inc. (February 1995)          |  |  |                |
|                                 | NPL30                 | Morea, V., et al., "Antibody Modeling: Implications for Engineering and Design," <i>Methods</i> 20:267-279, Academic Press (March 2000)  |  |  |                |
| ▼                               | NPL31                 | Mülhauser, J., et al., "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," <i>Circulation</i> 88:I-475, Abstract No. 2558, American Heart Association (October 1993)                                  |  |  |                |

## NON PATENT LITERATURE DOCUMENTS

|                    |               |                 |  |
|--------------------|---------------|-----------------|--|
| Examiner Signature | /Celine Qian/ | Date Considered |  |
|--------------------|---------------|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| Substitute for form 1449/PTO  |                       | Complete if Known  |                |                        |                      |
|---|-----------------------|--|----------------|------------------------|----------------------|
|   |                       | Application Number   | 09/921,143     |                        |                      |
| <b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |                       | Filing Date  | August 3, 2001 |                        |                      |
| Sheet   | 4                     | of   | 5              | Attorney Docket Number | 1488.100000N/HCC/PAC |
| Examiner Initials*  | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published  |                |                        | T <sup>2</sup>       |
| CQ  | NPL32                 | Mülhauser, J., et al., "VEGF <sub>165</sub> Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo," <i>Circulation Res.</i> 77:1077-1086, American Heart Association, Inc (December 1995)  |                |                        |                      |
|   | NPL33                 | Oikawa, T., et al., "Three Isoforms of Platelet-Derived Growth Factors All Have the Capacity to Induce Angiogenesis In Vivo," <i>Biol. Pharm. Bull.</i> 17:1686-1688, Pharmaceutical Society of Japan (December 1994)  |                |                        |                      |
|   | NPL34                 | Pajusola, K., et al., "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," <i>Oncogene</i> 9:3545-3555, Stockton Press Ltd. (December 1994)  |                |                        |                      |
|   | NPL35                 | Pepper, M.S., et al., "In Vitro Angiogenic and Proteolytic Properties of Bovine Lymphatic Endothelial Cells," <i>Exp. Cell Res.</i> 210:298-305, Academic Press, Inc. (February 1994)  |                |                        |                      |
|   | NPL36                 | Plate, K.H., "From angiogenesis to lymphangiogenesis," <i>Nat. Med.</i> 7:151-152, Nature America, Inc. (February 2001)  |                |                        |                      |
|   | NPL37                 | Spranger, J. and Pfeiffer, A.F.H., "New concepts in pathogenesis and treatment of diabetic retinopathy," <i>Exp. Clin. Endocrinol. Diabetes</i> 109(Suppl. 2):S438-S450, J.A. Barth Verlag (2001)  |                |                        |                      |
|   | NPL38                 | Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Taylor & Francis (1999)  |                |                        |                      |
|   | NPL39                 | Symes, J.F., et al., "Angiogenesis: potential therapy for ischaemic disease," <i>Curr. Opin. Lipidol.</i> 5:305-312, Current Science Ltd. (August 1994)  |                |                        |                      |
|   | NPL40                 | Takeshita, S. et al., "In Vivo Evidence of Enhanced Angiogenesis Following Direct Arterial Gene Transfer of the Plasmid Encoding Vascular Endothelial Growth Factor," <i>Circulation</i> 88, Abstract No. 2565, American Heart Association, Inc. (October 1993)                                  |                |                        |                      |
|   | NPL41                 | Takeshita, S., et al., "Therapeutic Angiogenesis. A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," <i>J. Clin. Invest.</i> 93:662-670, The American Society for Clinical Investigation, Inc. (February 1994) |                |                        |                      |
| ▼   | NPL42                 | Vale, P.R., et al., "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGI.1 (VEGF2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation (Suppl.)</i> 100:I-22, Lippincott Williams & Wilkins (November 1999)  |                |                        |                      |

|                    |               |                 |
|--------------------|---------------|-----------------|
| Examiner Signature | /Celine Qian/ | Date Considered |
|--------------------|---------------|-----------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |   |                          |                      |
|---|---|----|---|--------------------------|----------------------|
| Substitute for form 1449/PTO  |   |    |   | <i>Complete if Known</i> |                      |
| <b>NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><i>(Use as many sheets as necessary)</i> |   |    |   | Application Number       | 09/921,143           |
| Sheet   | 5 | of | 5 | Filing Date              | August 3, 2001       |
|   |   |    |   | First Named Inventor     | Coleman, Timothy A.  |
|   |   |    |   | Art Unit                 | 1636                 |
|   |   |    |   | Examiner Name            | Qian, Celine X.      |
|   |   |    |   | Attorney Docket Number   | 1488.100000N/HCC/PAC |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published   | T <sup>2</sup> |
|--------------------|-----------------------|---|----------------|
| CQ                 | NPL43                 | Verma, I. and Somia, N., "Gene therapy - promises, problems and prospects," <i>Nature</i> 389:239-242, Macmillan Magazines Ltd. (September 1997)  |                |
|                    | NPL44                 | Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res.</i> 3:147-153, BioMed Central Ltd. (February 2001)   |                |
|                    | NPL45                 | Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," <i>Am. J. Med. Sci.</i> 306:129-136, Lippincott Williams & Wilkins (August 1993)   |                |
|                    | NPL46                 | Witzenbichler, B., et al., "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," <i>Am. J. Pathol.</i> 153:381-394, American Society for Investigative Pathology, Inc. (August 1998)  |                |
|                    | NPL47                 | Yeung, P.K.F., "VEGF-2 St Elizabeth's Medical Center," <i>Curr. Opin. Invest. Drugs</i> 2:796-8000, PharmaPress Ltd. (June 2001)  |                |
|                    | NPL48                 | Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a third progress report for a project entitled "Cloning and expression of VEGF-2 gene and the efficacy of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated February 16, 2006. |                |
| ▼                  | NPL49                 | Letter from John J. Chicca II, Ph.D., Molecular Diagnostic Services, Inc. regarding a fourth progress report for a project entitled "Cloning and expression of VEGF-2 protein utilizing the 3-D collagen angiogenesis assay and proliferation," dated march 14, 2006.                                   |                |
|                    |                       |   |                |
|                    |                       |   |                |
|                    |                       |   |                |

504074\_1.DOC

|                    |   |                 |  |
|--------------------|---|-----------------|--|
| Examiner Signature | Celine Qian <small>Digitally signed by Celine Qian<br/>On 2006-08-12 17:33:24-04'00</small> | Date Considered |  |
|--------------------|---|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.